MX2020011344A - Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. - Google Patents

Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.

Info

Publication number
MX2020011344A
MX2020011344A MX2020011344A MX2020011344A MX2020011344A MX 2020011344 A MX2020011344 A MX 2020011344A MX 2020011344 A MX2020011344 A MX 2020011344A MX 2020011344 A MX2020011344 A MX 2020011344A MX 2020011344 A MX2020011344 A MX 2020011344A
Authority
MX
Mexico
Prior art keywords
methods
adrenal rest
rest tumors
ovarian
tumors
Prior art date
Application number
MX2020011344A
Other languages
English (en)
Inventor
Alexis Howerton
Hal Gerber
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of MX2020011344A publication Critical patent/MX2020011344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente compuestos y composiciones farmacéuticas para la prevención o tratamiento de tumores en reposo suprarrenales testiculares (TART) o tumores en reposo suprarrenales de ovarios (OART).
MX2020011344A 2018-04-27 2019-04-26 Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. MX2020011344A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663951P 2018-04-27 2018-04-27
US201962822815P 2019-03-23 2019-03-23
PCT/US2019/029486 WO2019210266A1 (en) 2018-04-27 2019-04-26 Methods for treating testicular and ovarian adrenal rest tumors

Publications (1)

Publication Number Publication Date
MX2020011344A true MX2020011344A (es) 2021-02-09

Family

ID=68295784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011344A MX2020011344A (es) 2018-04-27 2019-04-26 Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.

Country Status (9)

Country Link
US (2) US11304950B2 (es)
EP (1) EP3784233B1 (es)
JP (1) JP7427655B2 (es)
CN (1) CN112423747A (es)
AU (2) AU2019260793B2 (es)
BR (1) BR112020024062A2 (es)
CA (1) CA3098562A1 (es)
MX (1) MX2020011344A (es)
WO (1) WO2019210266A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
JP7427655B2 (ja) 2018-04-27 2024-02-05 スプルース バイオサイエンシーズ，インク． 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
BR112022000956A2 (pt) 2019-07-19 2022-04-05 Spruce Biosciences Inc Métodos de tratamento da hiperplasia adrenal congênita
WO2022036123A1 (en) 2020-08-12 2022-02-17 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2022046905A1 (en) * 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) * 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH0971528A (ja) * 1995-07-05 1997-03-18 Hayashibara Biochem Lab Inc 抗腫瘍剤
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
PL2094709T3 (pl) 2006-09-20 2011-02-28 Lilly Co Eli Tiazolopirazolopirymidyny jako antagoniści receptora crf1
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
KR102644781B1 (ko) * 2017-08-14 2024-03-06 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
MX2019015320A (es) * 2017-08-14 2020-07-20 Spruce Biosciences Inc Antagonistas del receptor del factor liberador de corticotropina.
JP7427655B2 (ja) 2018-04-27 2024-02-05 スプルース バイオサイエンシーズ，インク． 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法

Also Published As

Publication number Publication date
EP3784233A4 (en) 2022-03-02
US20220211711A1 (en) 2022-07-07
US20210038604A1 (en) 2021-02-11
EP3784233A1 (en) 2021-03-03
AU2023203095A1 (en) 2023-06-08
JP2021522340A (ja) 2021-08-30
BR112020024062A2 (pt) 2021-02-09
CN112423747A (zh) 2021-02-26
EP3784233B1 (en) 2024-06-05
AU2019260793A1 (en) 2020-12-17
AU2019260793B2 (en) 2023-05-18
WO2019210266A1 (en) 2019-10-31
CA3098562A1 (en) 2019-10-31
US11304950B2 (en) 2022-04-19
JP7427655B2 (ja) 2024-02-05

Similar Documents

Publication Publication Date Title
MX2020011344A (es) Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2021005314A (es) Compuestos biciclicos.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018011194A (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX369369B (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
PH12017501879A1 (en) Methods for treating cancer
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
WO2019023315A3 (en) RAC INHIBITORS
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2021006102A (es) Suministro mejorado de agentes grandes.
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
PH12019502915A1 (en) Immunogenic compositions
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.